Skip to main content

Table 1 Comparisons between various groups in terms of hemorrhagic complications

From: Thrombocytopenic patients with hematological malignancy who underwent fiberoptic bronchoscopy are they really under a significant hemorrhagic risk?

Variable

Hemorrhagic complication present

Hemorrhagic complication nonpresent

p value

Gender

 Female

1 (3.33)

29 (96.67)

1000

 Male

2 (2.38)

82 (97.62)

İmmunosuppressive therapy

 Receive

3 (2.86)

102 (97.14)

1000

 Not receive

0 (0.00)

9 (100.00)

Indication of bronchoscopy

 Pulmonary infiltrates

3 (2.73)

107 (97.27)

1000

 İinfiltrates and hemoptysis

0 (0.00)

3 (100.00)

 Hemoptysis

0 (0.00)

1 (100.00)

Platelet replacement

 Yes

3 (3.49)

83 (96.51)

1000

 No

0 (0.00)

28 (100.00)

Group according to platelet count

 Platelet count 0–30 K/mm3

1 (3.13)

31 (96.88)

0.624

 platelet count 30–50 K/mm3

0 (0.00)

35 (100.00)

 platelet count 50–100 K/mm3

2 (4.26)

45 (95.74)

PT (second)

 PT > 17

1 (9.09)

10 (90.91)

0.265

 PT < 17

2 (1.94)

101 (98.06)

INR

 INR> 1.5

1 (9.09)

10 (90.91)

0.265

 INR < 1.5

2 (1.94)

101 (98.06)

Urea (mg/dl)

 Blood urea > 50

1 (9.09)

10 (90.91)

0.265

 Blood urea < 50

2 (1.94)

101 (98.06)

İntervention type

 Only Bronchoalveolar lavage

3 (2,83)

103 (97.17)

0.257

 Bronchoalveolar lavage and brush swab

0 (0.00)

3 (100.00)

 Bronchoalveolar lavage and mucosal biopsy

0 (0.00)

4 (100.00)

 Bronchoalveolar lavage, brush swab and mucosal biopsy

0 (0.00)

1 (100.00)

BTS classification group

 No evidence of bleeding

0 (0.00)

111 (100.00)

< 0.001

 No bleeding

1 (100.00)

0 (0.00)

 Mild bleeding

1 (100.00)

0 (0.00)